A Critical Look at Innovation Profile and Its Relationship with Pharmaceutical Industry

Prata, Wallace Mateus; Silvestre, Rodrigo Gomes; Godman, Brian; Martin, A. Daniel; Dias, Carolina Zampirolli; Dias, Eduardo Mário; Acircio, Franciso de Assis; Júnior, Augusto Afonso Guerra

doi:10.18535/ijsrm/v5i7.20

Cited by 3 publications

(1 citation statement)

References 143 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Existem mecanismos de TT, desde as mais originárias, realizadas por meio das pesquisas de novidades de universidades para o setor privado, até transferências incentivadas para suprir deficiências tecnológicas de países em desenvolvimento, como, por exemplo, acordos entre empresas privadas e públicas, os quais possibilitam o desenvolvimento continuado para futuras inovações 17 .…”

Section: Transferência De Tecnologiaconceito E Desafios No Brasilunclassified

Estratégias de inovação em medicamentos e vacinas no âmbito do Ceis – modelos, mecanismos e expectativas

Fernandes,

Gadelha,

Maldonado

2023

Saúde debate

View full text Add to dashboard Cite

RESUMO O artigo objetivou apresentar informações relevantes e originais sobre as estratégias de inovação utilizadas por Laboratórios Farmacêuticos Oficiais (LFO) para redução das vulnerabilidades do Sistema Único de Saúde (SUS) e capacitação produtiva e tecnológica do Complexo Econômico-Industrial da Saúde. Como métodos, foram utilizadas a revisão da literatura e a análise de dados primários oriundos de entrevistas realizadas em dois dos maiores LFO do País. Foram identificados e analisados os seus esforços e resultados em Pesquisa e Desenvolvimento (P&D) assim como a incorporação de tecnologias de medicamentos e vacinas, com destaque para as Parcerias para Desenvolvimento Produtivo (PDP). Conclui-se que, apesar de as atividades de P&D ainda precisarem avançar, benefícios foram trazidos pelos acordos de transferência de tecnologia, especialmente pelas PDP. No entanto, a capacidade industrial e tecnológica dos Institutos ainda é limitada e carente de investimentos, dificultando a acumulação e a difusão tecnológica. Dessa forma, melhorias são necessárias para que as estratégias de inovação para o SUS apresentem resultados mais efetivos e possam ser revertidos para o bem-estar da sociedade.

show abstract

Section: Transferência De Tecnologiaconceito E Desafios No Brasilunclassified

Estratégias de inovação em medicamentos e vacinas no âmbito do Ceis – modelos, mecanismos e expectativas

Fernandes,

Gadelha,

Maldonado

2023

Saúde debate

View full text Add to dashboard Cite

show abstract

Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets

Godman

Bucsics²,

Bonanno

et al. 2018

Front. Public Health

131

137

View full text Add to dashboard Cite

Introduction: There is continued unmet medical need for new medicines across countries especially for cancer, immunological diseases, and orphan diseases. However, there are growing challenges with funding new medicines at ever increasing prices along with funding increased medicine volumes with the growth in both infectious diseases and non-communicable diseases across countries. This has resulted in the development of new models to better manage the entry of new medicines, new financial models being postulated to finance new medicines as well as strategies to improve prescribing efficiency. However, more needs to be done. Consequently, the primary aim of this paper is to consider potential ways to optimize the use of new medicines balancing rising costs with increasing budgetary pressures to stimulate debate especially from a payer perspective.Methods: A narrative review of pharmaceutical policies and implications, as well as possible developments, based on key publications and initiatives known to the co-authors principally from a health authority perspective.Results: A number of initiatives and approaches have been identified including new models to better manage the entry of new medicines based on three pillars (pre-, peri-, and post-launch activities). Within this, we see the growing role of horizon scanning activities starting up to 36 months before launch, managed entry agreements and post launch follow-up. It is also likely there will be greater scrutiny over the effectiveness and value of new cancer medicines given ever increasing prices. This could include establishing minimum effectiveness targets for premium pricing along with re-evaluating prices as more medicines for cancer lose their patent. There will also be a greater involvement of patients especially with orphan diseases. New initiatives could include a greater role of multicriteria decision analysis, as well as looking at the potential for de-linking research and development from commercial activities to enhance affordability.Conclusion: There are a number of ongoing activities across countries to try and fund new valued medicines whilst attaining or maintaining universal healthcare. Such activities will grow with increasing resource pressures and continued unmet need.

show abstract

Study of exaptation evidence in clinical research for delivering pharmaceutical innovation

Stamenović¹

2021

Revizor

View full text Add to dashboard Cite

Exaptation is a process that is characterized by the evolution of characteristics, its evolution for other usages, and later coopted for their current role. In the pharmaceutical industry, innovations have high potential in terms of competitive advantage and profit but are also connected with high risks associated with costs, time, and uncertainty. To minimize risks, companies frequently choose the strategy of exaptation in terms of redeveloping compounds for use in a different disease. The intention of this research is to provide analysis and quantification (measurement) of drugs that have been exaptated through the process of drug reposition. Results indicate that on level of 6098 clinical studies Phase I, we have observed a total of 659 drugs/substances (~11%) that have been used in more than one clinical research for the same or different indication showing the level of exaptation use in clinical research.

show abstract

A Critical Look at Innovation Profile and Its Relationship with Pharmaceutical Industry

Cited by 3 publications

References 143 publications

Estratégias de inovação em medicamentos e vacinas no âmbito do Ceis – modelos, mecanismos e expectativas

Estratégias de inovação em medicamentos e vacinas no âmbito do Ceis – modelos, mecanismos e expectativas

Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets

Study of exaptation evidence in clinical research for delivering pharmaceutical innovation

Contact Info

Product

Resources

About